Regeneron Pharmaceuticals, Inc. (REGN)
After hours:
| Previous Close | 906.54 |
| Open | 912.68 |
| Bid | 889.93 x 100 |
| Ask | 891.41 x 100 |
| Day's Range | 877.13 - 915.00 |
| 52 Week Range | 684.81 - 998.33 |
| Volume | |
| Avg. Volume | 466,462 |
| Market Cap | 99.503B |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | 26.04 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
EXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
- Zacks
Regeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
